Pictet Asset Management (UK)’s Acadia Pharmaceuticals ACAD Stock Holding History

Pictet Asset Management (UK)’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$25.7M	Sell	1,055,164 -27,660	-3%	-$624K	0.03%	474
2021 Q1	$27.9M	Sell	1,082,824 -596,915	-36%	-$26.3M	0.03%	435
2020 Q4	$89.8M	Sell	1,679,739 -556,124	-25%	-$27.6M	0.12%	216
2020 Q3	$92.2M	Buy	2,235,863 +184,042	+9%	+$7.95M	0.14%	185
2020 Q2	$99.5M	Buy	2,051,821 +625,439	+44%	+$30M	0.17%	167
2020 Q1	$60.3M	Buy	1,426,382 +218,707	+18%	+$9.01M	0.13%	194
2019 Q4	$51.7M	Buy	1,207,675 +237,425	+24%	+$10.3M	0.09%	256
2019 Q3	$34.9M	Buy	970,250 +611,750	+171%	+$18.5M	0.07%	294
2019 Q2	$9.58M	Buy	358,500 +74,700	+26%	+$1.91M	0.02%	536
2019 Q1	$7.62M	Buy	283,800 +88,000	+45%	+$2.06M	0.02%	598
2018 Q4	$3.17K	Buy	195,800 +57,300	+41%	+$1.11M	0.01%	755
2018 Q3	$2.88M	Sell	138,500 -9,000	-6%	-$142K	0.01%	851
2018 Q2	$2.25M	Sell	147,500 -554,333	-79%	-$9.88M	0.01%	796
2018 Q1	$15.8M	Sell	701,833 -719,027	-51%	-$19.9M	0.04%	421
2017 Q4	$42.8M	Buy	1,420,860 +88,805	+7%	+$2.84M	0.11%	245
2017 Q3	$50.2M	Buy	1,332,055 +386,217	+41%	+$12.6M	0.14%	202
2017 Q2	$24.3M	Buy	945,838 +161,600	+21%	+$4.82M	0.07%	313
2017 Q1	$27M	Sell	784,238 -48,576	-6%	-$1.71M	0.09%	291
2016 Q4	$24M	Sell	832,814 -97,197	-10%	-$2.57M	0.09%	281
2016 Q3	$29.6M	Buy	930,011 +95,284	+11%	+$3.23M	0.11%	237
2016 Q2	$29.6M	Buy	834,727 +523,511	+168%	+$17.5M	0.12%	233
2016 Q1	$5.37M	Buy	311,216 +72,189	+30%	+$1.57M	0.02%	524
2015 Q4	$8.52M	Buy	239,027 +91,382	+62%	+$3.22M	0.04%	438
2015 Q3	$4.88M	Sell	147,645 -104,091	-41%	-$4.33M	0.02%	563
2015 Q2	$12.3M	Buy	251,736 +147,872	+142%	+$5.72M	0.05%	388
2015 Q1	$3.55M	Buy	+103,864	New	+$3.57M	0.01%	656

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Pictet Asset Management (UK)'s ACAD Position: Q2 2021 in Review

Pictet Asset Management (UK) reduced its Acadia Pharmaceuticals (ACAD) stake by 2.6% in Q2 2021, selling an estimated $624K and leaving 1,055,164 shares worth $25.7M. The position accounts for 0.03% of the portfolio, ranked #474.

Pictet Asset Management (UK) first reported a position in ACAD in Q1 2015 and has held it in 26 quarters since. The position peaked at $99.5M in Q2 2020. 244 funds tracked by Wall St. Rank hold ACAD as of Q2 2021.

Pictet Asset Management (UK) held 1,055,164 shares of Acadia Pharmaceuticals worth $25.7M as of Q2 2021.
Pictet Asset Management (UK) sold 27,660 Acadia Pharmaceuticals shares in Q2 2021, an estimated $624K.
Acadia Pharmaceuticals made up 0.03% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #474 holding.
Pictet Asset Management (UK) first reported a position in Acadia Pharmaceuticals in Q1 2015 and has held it in 26 quarters since.
Pictet Asset Management (UK)'s Acadia Pharmaceuticals position peaked at $99.5M in Q2 2020.
244 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.